Payment overview · 2025
General Payments
$362.22
20 reported records · 4 companies
Healthcare provider profile · identity verified
Agustin Rubio, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · REEDLEY, CA · NPI 1417131236
Verified facts
What the public records show
CMS Open Payments records show Agustin Rubio, M.D. received $362.22 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 57.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 379 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 666 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $208.34 | 57.5% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $90.84 | 25.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.72 | 11.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.32 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $362.22 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.34 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $90.84 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.70 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.70 | 4 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 379 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 666 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
379 | 81 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
666 | 98 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1030 | 278 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 812 | 109 |
| Ozempic | Semaglutide | 666 | 98 |
| Omeprazole | Omeprazole | 657 | 150 |
| Lisinopril | Lisinopril | 478 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 452 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 447 | 140 |
| Jardiance | Empagliflozin | 379 | 81 |
| Metformin Hcl | Metformin Hcl | 365 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 305 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 83 |
| Gabapentin | Gabapentin | 296 | 63 |
| Pioglitazone Hcl | Pioglitazone Hcl | 274 | 72 |
| Alendronate Sodium | Alendronate Sodium | 270 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 253 | 80 |
| Tramadol Hcl | Tramadol Hcl | 247 | 51 |
| Famotidine | Famotidine | 238 | 60 |
| Trazodone Hcl | Trazodone Hcl | 238 | 50 |
| Farxiga | Dapagliflozin Propanediol | 235 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 203 | 40 |
| Finasteride | Finasteride | 201 | 52 |
| Linzess | Linaclotide | 183 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 67 |
| Carvedilol | Carvedilol | 163 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 163 | 75 |
| Furosemide | Furosemide | 161 | 59 |
| Ibuprofen | Ibuprofen | 151 | 57 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 145 | 81 |
| Glimepiride | Glimepiride | 144 | 41 |
| Losartan Potassium | Losartan Potassium | 136 | 42 |
| Eliquis | Apixaban | 131 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 131 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 29 |
| Alprazolam | Alprazolam | 125 | 20 |
| Telmisartan | Telmisartan | 121 | 37 |
| Rybelsus | Semaglutide | 120 | 22 |
| Chlorthalidone | Chlorthalidone | 118 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 115 | 26 |
| Pregabalin | Pregabalin | 111 | 31 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 109 | 42 |
| Ondansetron Odt | Ondansetron | 109 | 40 |
| Allopurinol | Allopurinol | 108 | 23 |
| Spironolactone | Spironolactone | 108 | 35 |
| Baclofen | Baclofen | 97 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 31 |
| Naproxen | Naproxen | 90 | 31 |
| Mirtazapine | Mirtazapine | 87 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | 18 |
| Bupropion Xl | Bupropion Hcl | 80 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 25 |
| Simvastatin | Simvastatin | 78 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 75 | 24 |
| Azithromycin | Azithromycin | 74 | 58 |
| Clonazepam | Clonazepam | 74 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 18 |
| Prednisone | Prednisone | 72 | 55 |
| Humalog Kwikpen U-100 | Insulin Lispro | 71 | 20 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 71 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 12 |
| Bumetanide | Bumetanide | 70 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 22 |
| Sertraline Hcl | Sertraline Hcl | 70 | 16 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 70 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | suppressed |
| Methadone Hcl | Methadone Hcl | 66 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 13 |
| Doxepin Hcl | Doxepin Hcl | 61 | 13 |
| Mounjaro | Tirzepatide | 58 | 15 |
| Trulicity | Dulaglutide | 58 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 46 |
| Tradjenta | Linagliptin | 56 | 14 |
| Meclizine Hcl | Meclizine Hcl | 53 | 29 |
| Nifedipine Er | Nifedipine | 53 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 52 | 17 |
| Topiramate | Topiramate | 52 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 51 | 16 |
| Fluconazole | Fluconazole | 50 | 25 |
| Lubiprostone | Lubiprostone | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Celecoxib | Celecoxib | 47 | 13 |
| Potassium Chloride | Potassium Chloride | 47 | 20 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 45 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 43 | 12 |
| Entresto | Sacubitril/Valsartan | 42 | 11 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Meloxicam | Meloxicam | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 18 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 11 |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 15 |
| Ezetimibe | Ezetimibe | 39 | 15 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Novolog | Insulin Aspart | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Valsartan | Valsartan | 37 | 11 |
| Cephalexin | Cephalexin | 36 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 36 | 12 |
| Diazepam | Diazepam | 35 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 32 | 12 |
| Kerendia | Finerenone | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 20 |
| Amoxicillin | Amoxicillin | 29 | 26 |
| Breyna | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Eplerenone | Eplerenone | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 13 |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Minoxidil | Minoxidil | 26 | suppressed |
| Nystatin | Nystatin | 25 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 22 |
| Fentanyl | Fentanyl | 24 | suppressed |
| Indomethacin | Indomethacin | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 18 | 17 |
| Atenolol | Atenolol | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Prolia | Denosumab | 17 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 12 | suppressed |
| Alprazolam Odt | Alprazolam | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $362.22 · 20 records | Novo Nordisk Inc | BEXSERO, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, PEDIARIX, Rybelsus, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error